Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD ...Middle East

MISSISSAUGA, ON, Aug. 5, 2025 /PRNewswire/ - Kye Pharmaceuticals Inc. ("Kye"), a leading Canadian-based commercial-stage specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, is pleased to announce the Health Canada approval...

Hence then, the article about kye pharmaceuticals announces the approval of dyanavel xr amphetamine extended release tablets and oral suspension for the treatment of adults and children with adhd was published today ( Tuesday 05/08/2025 - 03:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD )

Also on site :

• I-70 closed in Glenwood Canyon for safety concerns, police activity
• What we know about the alleged arson at Mississippi’s largest and oldest synagogue
• Russian cat becomes world champion 2025